Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Depreciation & Amortization (CF) (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $153000.0 in Q1 2025.

  • For Q1 2025, Depreciation & Amortization (CF) fell 10.0% year-over-year to $153000.0; the TTM value through Dec 2025 reached $153000.0, down 76.09%, while the annual FY2024 figure was $640000.0, 20.0% down from the prior year.
  • Depreciation & Amortization (CF) reached $153000.0 in Q1 2025 per ARQT's latest filing, up from $145000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $227000.0 in Q4 2023 and bottomed at $98000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $158411.8, with a median of $157000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 420.0% in 2021, then tumbled 36.12% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $182000.0 in 2021, then dropped by 24.18% to $138000.0 in 2022, then skyrocketed by 64.49% to $227000.0 in 2023, then plummeted by 36.12% to $145000.0 in 2024, then rose by 5.52% to $153000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $153000.0 in Q1 2025, $145000.0 in Q4 2024, and $161000.0 in Q3 2024.